Our Ocular Expertise

ANEWCRO’s expertise in ophthalmic drug development enables the administration of compounds through multiple ocular dosing routes, including intravitreal, intracameral, subretinal, subchoroidal, and topical applications. Our specialized capabilities support a broad range of preclinical studies aimed at evaluating the safety, efficacy, and pharmacokinetics of ophthalmic therapies.

​

Our team is experienced in performing comprehensive ocular assessments to monitor drug effects and disease progression. These evaluations include detailed ophthalmic examinations conducted by trained specialists to assess corneal integrity, anterior chamber health, and retinal conditions.

We also measure intraocular pressure (IOP) to monitor potential drug-induced effects on aqueous humor dynamics, ensuring early detection of any adverse ocular responses. This is critical for assessing the safety profile of intraocular drug formulations, particularly for glaucoma and other pressure-sensitive conditions.

​

Additionally, we employ state-of-the-art optical coherence tomography (OCT) imaging to obtain high-resolution cross-sectional images of ocular structures. This non-invasive technique allows for precise monitoring of retinal thickness, choroidal changes, and drug-induced alterations in the eye, providing valuable insights into therapeutic effects.

​

By integrating multiple dosing routes with advanced ocular assessments, ANEWCRO offers a comprehensive approach to ophthalmic drug evaluation, supporting the development of innovative treatments for a wide range of ocular disorders.